MGTX - MeiraGTx Holdings PLC

Buy Momentum: Bearish

Recent News

MeiraGTx Holdings PLC ( MGTX ) Reports Q2 Loss, Beats Revenue Estimates

Zacks Commentary • 1 month ago • score: 0.13

MeiraGTx (MGTX) delivered earnings and revenue surprises of +7.69% and +59.78%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Neutral

MeiraGTx Holdings PLC ( MGTX ) Reports Q1 Loss, Misses Revenue Estimates

Zacks Commentary • 4 months ago • score: 0.04

MeiraGTx (MGTX) delivered earnings and revenue surprises of -34.21% and 76.85%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

MeiraGTx Holdings plc, a clinical-stage gene therapy company, focused on developing treatments for patients living with serious illnesses. The company is headquartered in New York, New York.

52W High

$8.98

52W Low

$3.86

MA Status:

50D: Below 200D: Above

Beta (~1 neutral, <0.9 lower risk)

1.30

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

1.62

EV/EBITDA (<8 favorable)

-3.29

EV/Revenue (<3 favorable)

17.59

P/S (TTM) (<3 favorable)

16.32

P/B (<3 favorable)

209.00

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

24.15%

Institutions (25–75% balanced)

64.98%

Shares Outstanding

80,448,000

Float

31,695,500

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

37,917,000

Gross Profit (TTM)

10,072,000

EPS (TTM)

-2.03

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-12.14%

ROE (TTM) (>15% strong)

-3.80%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

12.09

Momentum

Bearish momentum

Value

-0.0693

-0.0788

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025